Ademi & O'Reilly, LLP Investigates Possible Securities Fraud of Spectrum Pharmaceuticals, Inc.

MILWAUKEE, March 13, 2013 (GLOBE NEWSWIRE) -- We are investigating possible securities fraud claims against Spectrum Pharmaceuticals, Inc. resulting from inaccurate statements Spectrum made regarding its financial performance and future prospects for the period October 28, 2011 to March 12, 2013.

Click here to learn more about the investigation: or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Our investigation focuses on Spectrum's false and misleading statements regarding its financial performance and future prospects. Specifically, Spectrum was: (i) despite management denials, using discount pricing and other promotional tactics to sustain the sales stability of Fusilev, (ii) channel stuffing its wholesalers with stock of Fusilev to artificially increase the sales of Fusilev, and (iii) failing to disclose that hospitals were increasingly using generic alternatives to Fusilev.

If you wish to obtain additional information or have information about Spectrum, please contact Guri Ademi either at or toll-free: 866-264-3995,

We specialize in securities fraud and shareholder litigation. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Ademi & O'Reilly, LLP Guri Ademi 3620 East Layton Ave. Cudahy, WI 53110 Toll Free: (866) 264-3995 Fax: (414) 482-8001 www.ademilaw.comSource:Ademi & O'Reilly, LLP